MedPAC is considering whether to recommend reducing the 6% add-on to Part B drug reimbursement to decrease the incentives for providers to use higher-priced drugs.

MedPAC May Back a Cut in Part B Drug Payments, This Time Not for 340B Hospitals Only

Congressional Medicare advisers are weighing whether to recommend converting the 6% add-on to Part B drug reimbursement to a fixed fee capped at $175 for drugs that cost $15,000 or more, phased in starting with drugs costing above $700.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

*Sign up for news summaries and alerts from 340B Report